Commitments and Contingencies (Details Narrative) - USD ($)			1 Months Ended											3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 02, 2019	Dec. 03, 2018	Feb. 19, 2021	Jan. 29, 2021	Sep. 18, 2020	Jul. 31, 2020	Feb. 18, 2020	Nov. 27, 2019	Nov. 25, 2019	Nov. 24, 2019	Nov. 22, 2019	Aug. 22, 2017	Dec. 31, 2011	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020	Nov. 16, 2012	May 04, 2020	Apr. 24, 2020	Dec. 02, 2018	Oct. 26, 2018
Settlement of litigation					$ 200,000
Commitments and Contingencies												The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.
Litigation awards for damages		$ 315,695			384,771
Litigation awards, exercisable shares																				84,000	84,000
Exercise price																				$ 2.50	$ 2.50
Note amount																						$ 682,000
Accrued Liquidated damages					210,000
Accrued claim														$ 2,752,235		$ 2,752,235
Legal fees					93,304
Research and development														1,558,299	$ 599,837	2,728,307	$ 938,571
Payable to foundation for services						$ 1,315,817								1,315,817		1,315,817
Interest payable to foundation						$ 3,911,141								4,399,565		4,399,565
Interest accrued payable to foundation																488,424	408,512
Arbitration fees					12,393
Arbitration expenses					3,313
Proceeds from refundable advances																2,000,000
Bonus														7,060,417		$ 7,060,417
Pre-judgment interest					$ 65,762
Bonus compensation description																Company awarded executives and employees bonus compensation of $7,060,417 to be paid in approximately $1 million in cash and $6 million in stock.
Payment for legal settlement																$ 350,140
Accrued claim														3,850,320		3,850,320
Olaregen
Intellectual property acquired								$ 650,000
AEXG [Member]
Litigation awards for damages				$ 3,300,000										3,748,177
Legal fees				$ 550,320
NDS
Accrued claim														3,416,695		3,416,695
KSKZ Management [Member]
Consulting fees	$ 3,450,000
Damages							$ 2,475,000
Discover Growth Fund [Member]
Litigation awards for damages																2,200,000
Accrued claim														2,500,000		2,500,000			$ 2,200,000
Legal fees																53,312
Discover Growth Fund [Member] | Subsequent Event [Member]
Payment for legal settlement			$ 2,253,312
Iliad [Member]
Shares issued for litigation settlement						3,499,415
ALTuCELL [Member]
Common stock description											Under the SPA, in exchange for the ALTuCELL Stock, Generex will issue to ALTuCELL 2,240,000 shares of Generex common stock with an attributed value of $4 million to be issued at the market price of the day at closing, but no less than $0.89 per share. The Company will also pay $2.5 million in cash of which $212,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCELL upon ALTuCELL’s attainment of certain milestones.
Advanced to related party														212,000		212,000
Alternative Execution Group [Member]
Memorandum of Understanding description		The petition includes a demand of $3,300,360 as the value of the warrants. The arbitrator did not award the specific amount of $3.5 million, but only liquidated damages in the amount of $210,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees.
Olaregen
Stock Purchase Agreement description										Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock (the “Olaregen Note”). Effective November 24, 2019, the deadline was extended to January 31, 2020.
Regentys
Stock Purchase Agreement description									Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 were all payable on or before December 30, 2019. The Company is negotiating the terms of a new extension and there has been no demand for payment at this time.
NSABP [Member] | Clinical trial agreement [Member]
Accrued claim														1,120,637		1,120,637
Research and development																80,000	$ 251,459
Cellular Technology Limited [Member] | Clinical trial agreement [Member]
Research and development														$ 562,063		1,115,940
Damages for Unpaid Invoices
Value of damages sought													$ 429,000
Lawsuit filing date													31-Dec-11
Name of Plaintiff													Vendor
Settlement of litigation																		$ 125,000
Interest per annum, failure to pay settlement													3.00%
Fixed cost per annum, failure to pay settlement																$ 25,000
Breach of contract and detinue
Counterclaim proceeding													$ 200,000